A Risk Stratification Model for Predicting Chemotherapy Benefit in Breast Neuroendocrine Carcinoma: A Population-Based Analysis

Lu-tong Yan,Yu-ting Zhao,Jia-shu Song,Bo-hao Liu,Shou-yu Li,He-yan Chen,Sheng-yu Pu,Mi Miao,Jian-Jun He,Xiao-jiang Tang,Na Hao
DOI: https://doi.org/10.1016/j.ctarc.2024.100853
2024-01-01
Cancer Treatment and Research Communications
Abstract:Background: Breast Neuroendocrine neoplasms (Br-NENs) is a rare entity with unclear chemotherapy treatment options. This study is aimed to screen out patients with Br-NENs who benefit from chemotherapy. Methods: A total of 340 patients with Br-NENs were enrolled in the SEER database between 2010-2020. Propensity score matching (PSM) was performed to balance the clinical baseline. Prognostic factors determined by multivariate Cox analysis were included in the nomogram. C-index and calibration curves were used to verify the performance of the nomogram. K-M curves were used to evaluate the overall survival benefit of chemotherapy in different risk group. Results: A ratio of 5:1 was used to randomly split them into a training set and a validation set. Next, a nomogram predicating 1-, 3- and 5-year OS rates was constructed based on the six independent factors (TNM stage, surgery, Br-NENs, breast subtype, brain metastasis and liver metastasis). The nomogram AUCs for 1-, 3- and 5-year OS (training set: 0.888, 0.791 and 0.777; validation set: 0.944, 0.831 and 0.861) and calibrations plots exhibited good discriminative and predictive ability. Additionally, a novel risk classification system for Br-NENs patients demonstrated that we recommended receiving chemotherapy for the high-risk group (total population: P=0.0063; training set: P=0.031). Conclusion: Our results suggested that clinicians should recommend receiving chemotherapy for the high-risk group based on a combination of factors and that the possibility of exemption from chemotherapy should be confirmed by more clinical trials in the future.
What problem does this paper attempt to address?